Re: Zoledronic acid initiated during the first year of androgen deprivation therapy increases bone mineral density in patients with prostate cancer: C. W. Ryan, D. Huo, L. M. Demers, T. M. Beer and L. V. Lacerna. J Urol 2006; 176: 972-978.
Gilbert
Scott M
SM
Dunn
Rodney L
RL
Wei
John T
JT
D015519:Bone Density / Q000187:drug effects*; D050071:Bone Density Conservation Agents / Q000627:therapeutic use*; D004164:Diphosphonates / Q000627:therapeutic use*; D050723:Fractures, Bone / Q000209:etiology / Q000517:prevention & control*; D007987:Gonadotropin-Releasing Hormone / Q000009:adverse effects / Q000819:agonists; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use*; D008297:Male; D009919:Orchiectomy / Q000009:adverse effects; D011471:Prostatic Neoplasms / Q000628:therapy*; D012307:Risk Factors; D013997:Time Factors; D000077211:Zoledronic Acid
D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D007093:Imidazoles; D007987:Gonadotropin-Releasing Hormone; D000077211:Zoledronic Acid